AASLD2018[1073]伴随的脂肪肝疾病可能会导致 高血压对肝纤维化

StephenW

1073
Accompanying Fatty Liver Disease May Lead
to Overestimation of Liver Fibrosis By Liver
Stiffness Measurement in Hepatitis B Patients
Lu Liu, The Third Central Clinical College of Tianjin Medical
University, Fang Liu, Department of Hepatology and
Gastroenterology, Ianjin Third Central Hospital of Tianjin and
Tao Han, Department of Gastroenterology and Hepatology,
Tianjin Third Central Hospital
Background: he impact of hepatic steatosis on the diagnostic
capability of liver stiffness measurement(LSM) in hepatitis B
patients have not been completely investigated. In this study,
we aimed to explore the association between existence of
fatty liver disease(FLD) and the diagnostic performance of
LSM among hepatitis B patients in a medical center in Tianjin,
China.Methods: A total of 952 hepatitis B patients who
underwent a transient elastography examination at Tianjin
Third Center Hospital between Mar 2014 and Dec 2017 were
included. All patients were divided into two groups depended
on with or without cirrhosis. The diagnosis of liver cirrhosis
was based on comprehensive analysis of clinical diagnosis,
laboratory data, abdominal ultrasonography and LSM score.
Patients without cirrhosis were further grouping according to
the combination of FLD exist, which detected by abdominal
ultrasonography.Results: We analyzed the continuous
variable of non-cirrhosis group. The results showed that there
were marked differences in body mass index(BMI) values,
controlled attenuation parameter (CAP) score and LSM
values between FLD group and non-FLD group. BMI values
(kg/m2) was 27.34(25.22,28.68), 23.74(20.59,25.76) in FLD
group and non-FLD group, respectively (P < 0.001).CAP score
(dB/m) was 255.47(238.93,277.83), 224.66(208.54, 234.81)
in FLD group and non-FLD group, respectively (P < 0.001).
The LSM values (kPa) were 7.54(6.56,8.54), 6.39(5.32,7.00)
in FLD group and non-FLD group, respectively (P < 0.001).
Multivariate linear regression analysis of all study patients
showed that higher CAP (B=0.098, P=0.006) were positively
related to LSM, BMI were no significantly association with
LSM. Conclusion: LSM in hepatitis B patients with FLD
have higher LSM values which may lead to overestimation of
fibrosis in these patients.

StephenW

1073
伴随的脂肪肝疾病可能会导致
高血压对肝纤维化的高估
乙型肝炎患者的僵硬度测量
天津医学院第三中心临床学院陆柳
大学，刘芳，肝病学系
天津市Ianjin第三中心医院消化内科
陶汉，消化内科和肝病学系，
天津市第三中心医院
背景：肝脏脂肪变性对诊断的影响
乙肝肝硬度测量（LSM）的能力
患者尚未完全被调查。在这个研究中，
我们旨在探讨存在之间的关联
脂肪肝（FLD）及其诊断性能
天津医疗中心乙型肝炎患者的LSM，
中国。方法：共有952名乙型肝炎患者
在天津接受了一次短暂的弹性成像检查
2014年3月至2017年12月期间的第三中心医院
包括在内。所有患者分为两组
有或没有肝硬化。肝硬化的诊断
基于对临床诊断的综合分析，
实验室数据，腹部超声检查和LSM评分。
没有肝硬化的患者根据进一步分组
存在FLD的组合，其通过腹部检测
超声检查。结果：我们分析了连续性
非肝硬化组的变量。结果显示有
体重指数（BMI）值明显不同，
受控衰减参数（CAP）得分和LSM
FLD组和非FLD组之间的值。 BMI值
FLD（kg / m2）为27.34（25.22,28.68），23.74（20.59,25.76）
组和非FLD组分别（P <0.001）.CAP评分
（dB / m）为255.47（238.93,277.83），224.66（208.54,234.81）
FLD组和非FLD组分别（P <0.001）。
LSM值（kPa）为7.54（6.56,8.54），6.39（5.32,7.00）
FLD组和非FLD组分别（P <0.001）。
所有研究患者的多元线性回归分析
表明较高的CAP（B = 0.098，P = 0.006）为正
与LSM相关，BMI与之无明显关联
LSM。结论：LSM治疗乙型肝炎患者FLD
具有较高的LSM值可能导致高估
这些患者的纤维化。